56 results
10-K
2024 FY
IXHL
Incannex Healthcare Limited
30 Sep 24
Annual report
7:30am
endpoint for the Phase 2 trial is pain and function relative to baseline determined via the score on the RAPID3 assessment at 24 weeks. Per the protocol … could include medication guides, physician communication plans, assessment plans and/or elements to assure safe use, such as restricted distribution
10-K
2024 FY
EX-10.9
IXHL
Incannex Healthcare Limited
30 Sep 24
Annual report
7:30am
of such a benefit has been sought and obtained by the Company.
21. Tax Matters.
(a) Subdivision 83A-C of the Income Tax Assessment Act 1997 applies
8-K
EX-99.1
IXHL
Incannex Healthcare Limited
5 Aug 24
FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed
8:15am
trial, PsiGAD2, is deemed safe to proceed following assessment of the trial protocol, lead trial investigator, and a risk benefit analysis … , healthcare utilisation, electroencephalography (EEG), as well as assessment of safety and tolerability through adverse event monitoring.
Incannex
8-K
EX-99.1
IXHL
Incannex Healthcare Limited
30 Jul 24
Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X
9:00am
anticipates greatly improved treatment compliance and outcomes from a pharmaceutical product, such as IHL-42X, subject to further clinical assessment
S-1/A
IXHL
Incannex Healthcare Limited
17 Jul 24
IPO registration (amended)
8:47am
on the agency’s assessment of the trial protocol, lead trial investigators, and a risk benefit analysis of the trial and prospective product. Clearance of the IND … -216A) in the Morris Water Maze assessment. Rodents that had undergone TBI and treated with CBD and/or isoflurane or vehicle were assessed for spatial
S-1
smoybn2xotyhnhallub
3 Jul 24
IPO registration
6:29am
8-K
EX-99.1
pneb 8oalgn
30 May 24
Other Events
8:30am
8-K
EX-99.1
od0 jgdw0
16 Apr 24
Incannex Healthcare Inc. Quarterly Update, Q1 2024
9:30am
8-K
EX-99.1
h9c1yic
24 Jan 24
Other Events
4:30pm
8-K
EX-99.1
eo4sxkew fkbmo29y
17 Jan 24
Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
6:05am
6-K
EX-99.1
5o4fj19650i9b qi
26 Oct 23
Incannex Healthcare September 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement
6:02am
6-K
EX-99.1
bwi rvvljnf71dv
1 Sep 23
Report of Foreign Private Issuer
12:00am
6-K
EX-99.1
vznf9i6wyt 0ne6r
22 Aug 23
Review of IND Application for IHL-42X by US FDA has been completed; Clinical Trial for Patients with Obstructive Sleep Apnoea May Proceed
6:01am
6-K
EX-99.1
uyzdl0f76n42
8 Aug 23
Clarion Clinics Begins Accepting Registrations for Psychedelic Treatment Interest as Part of Pre-Screening in Readiness for Opening
6:02am
6-K
EX-99.1
2djc0h2l1tf xq1fi5
27 Jul 23
Incannex Healthcare June 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement
8:47pm
6-K
EX-99.1
tk5vtw
25 Jul 23
Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-675A for Treatment of Rheumatoid Arthritis
9:42pm
6-K
EX-99.1
vb2 z5sjisbpdq
20 Jul 23
Incannex Submits IND Application to the US FDA for IHL-42X for Obstructive Sleep Apnoea
9:47pm
6-K
EX-99.1
a8g9ojc69 oj
18 Jul 23
Incannex engages Fortrea to Manage its FDA IND Opening Phase 2/3 Clinical Trial Investigating IHL-42X for Treatment of Obstructive Sleep Apnoea
6:04am